Resveratrol enhances the expression of death receptor Fas/CD95 and induces differentiation and apoptosis in anaplastic large-cell lymphoma cells

Cancer Letters

Volumn 309, Issue 1, 2011, Pages 46-53

  Ko, Ya Chen ^a   Chang, Chia Ling ^b,c   Chien, Hsiung Fei ^c   Wu, Ching Hsiang ^d   Lin, Liang In ^b,c  

^a YUANPEI UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Anaplastic large cell lymphoma; Apoptosis; Differentiation; Fas CD95; Resveratrol; SR 786

Indexed keywords

CD2 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; RESVERATROL;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL DIFFERENTIATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; IC 50; LARGE CELL LYMPHOMA; LYMPHOMA CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTICARCINOGENIC AGENTS; ANTIGENS, CD95; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA FRAGMENTATION; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; STILBENES;

VITACEAE;

EID: 79959834010     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.05.014     Document Type: Article

References (60)

1. Harikumar K.B., Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7:1020-1035.
2. Kimura Y., Okuda H., Arichi S. Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim. Biophys. Acta 1985, 834:275-278.
3. Goswami S.K., Das D.K. Resveratrol and chemoprevention. Cancer Lett. 2009, 284:1-6.
4. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
5. Clement M.V., Hirpara J.L., Chawdhury S.H., Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998, 92:996-1002.
6. Athar M., Back J.H., Tang X., Kim K.H., Kopelovich L., Bickers D.R., Kim A.L. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 2007, 224:274-283.
7. Cheng A.L., Su I.J., Chen C.C., Tien H.F., Lay J.D., Chen B.R., Pu Y.S., Hong R.L., Shen M.C., Wang C.H., et al. Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study. J. Clin. Oncol. 1994, 12:1185-1192.
8. Chou W.C., Su I.J., Tien H.F., Liang D.C., Wang C.H., Chang Y.C., Cheng A.L. Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma. Special emphasis on the tumor response to 13-cis retinoic acid. Cancer 1996, 78:1805-1812.
9. Wang K.C., Cheng A.L., Chuang S.E., Hsu H.C., Su I.J. Retinoic acid-induced apoptotic pathway in T-cell lymphoma: Identification of four groups of genes with differential biological functions. Exp. Hematol. 2000, 28:1441-1450.
10. Smith W., Saba N. Retinoids as chemoprevention for head and neck cancer: where do we go from here?. Crit. Rev. Oncol. Hematol. 2005, 55:143-152.
11. Su I.J., Balk S.P., Kadin M.E. Molecular basis for the aberrant expression of T cell antigens in postthymic T cell malignancies. Am. J. Pathol. 1988, 132:192-198.
12. Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G. The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines. Leukemia 1996, 10:142-149.
13. Pace-Asciak C.R., Hahn S., Diamandis E.P., Soleas G., Goldberg D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta 1995, 235:207-219.
14. Bernhard D., Tinhofer I., Tonko M., Hubl H., Ausserlechner M.J., Greil R., Kofler R., Csordas A. Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells. Cell Death Differ. 2000, 7:834-842.
15. Ahmad N., Adhami V.M., Afaq F., Feyes D.K., Mukhtar H. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin. Cancer Res. 2001, 7:1466-1473.
16. Adhami V.M., Afaq F., Ahmad N. Involvement of the retinoblastoma (pRb)-E2F/DP pathway during antiproliferative effects of resveratrol in human epidermoid carcinoma (A431) cells. Biochem. Biophys. Res. Commun. 2001, 288:579-585.
17. Reagan-Shaw S., Afaq F., Aziz M.H., Ahmad N. Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin. Oncogene 2004, 23:5151-5160.
18. Lanzilli G., Fuggetta M.P., Tricarico M., Cottarelli A., Serafino A., Falchetti R., Ravagnan G., Turriziani M., Adamo R., Franzese O., Bonmassar E. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Int. J. Oncol. 2006, 28:641-648.
19. Yan Y., Gao Y.Y., Liu B.Q., Niu X.F., Zhuang Y., Wang H.Q. Resveratrol-induced cytotoxicity in human Burkitt's lymphoma cells is coupled to the unfolded protein response. BMC Cancer 2010, 10:445.
20. Cecconi D., Zamo A., Parisi A., Bianchi E., Parolini C., Timperio A.M., Zolla L., Chilosi M. Induction of apoptosis in Jeko-1 mantle cell lymphoma cell line by resveratrol: a proteomic analysis. J. Proteome Res. 2008, 7:2670-2680.
21. Cecchinato V., Chiaramonte R., Nizzardo M., Cristofaro B., Basile A., Sherbet G.V., Comi P. Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem. Pharmacol. 2007, 74:1568-1574.
22. Faber A.C., Chiles T.C. Resveratrol induces apoptosis in transformed follicular lymphoma OCI-LY8 cells: evidence for a novel mechanism involving inhibition of BCL6 signaling. Int. J. Oncol. 2006, 29:1561-1566.
23. Faber A.C., Dufort F.J., Blair D., Wagner D., Roberts M.F., Chiles T.C. Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas. Biochem. Pharmacol. 2006, 72:1246-1256.
24. Jazirehi A.R., Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol. Cancer Ther. 2004, 3:71-84.
25. Bertelli A.A., Giovannini L., Stradi R., Bertelli A., Tillement J.P. Plasma, urine and tissue levels of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int. J. Tissue React. 1996, 18:67-71.
26. Meng X., Maliakal P., Lu H., Lee M.J., Yang C.S. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J. Agric. Food Chem. 2004, 52:935-942.
27. Goldberg D.M., Yan J., Soleas G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 2003, 36:79-87.
28. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32:1377-1382.
29. Crowell J.A., Korytko P.J., Morrissey R.L., Booth T.D., Levine B.S. Resveratrol-associated renal toxicity. Toxicol. Sci. 2004, 82:614-619.
30. Boocock D.J., Faust G.E., Patel K.R., Schinas A.M., Brown V.A., Ducharme M.P., Booth T.D., Crowell J.A., Perloff M., Gescher A.J., Steward W.P., Brenner D.E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1246-1252.
31. Almeida L., Vaz-da-Silva M., Falcao A., Soares E., Costa R., Loureiro A.I., Fernandes-Lopes C., Rocha J.F., Nunes T., Wright L., Soares-da-Silva P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res 2009, 53(Suppl. 1):S7-15.
32. Cottart C.H., Nivet-Antoine V., Laguillier-Morizot C., Beaudeux J.L. Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 2010, 54:7-16.
33. Collins M.K., Tanigawa G., Kissonerghis A.M., Ritter M., Price K.M., Tonegawa S., Owen M.J. Regulation of T-cell receptor gene expression in human T-cell development. Proc. Natl. Acad. Sci. USA 1985, 82:4503-4507.
34. Knowles D.M. Immunophenotypic and antigen receptor gene rearrangement analysis in T cell neoplasia. Am. J. Pathol. 1989, 134:761-785.
35. Ghia P., Prato G., Stella S., Scielzo C., Geuna M., Caligaris-Cappio F. Age-dependent accumulation of monoclonal CD4+CD8+ double positive T lymphocytes in the peripheral blood of the elderly. Brit. J. Haematol. 2007, 139:780-790.
36. Rahemtullah A., Harris N.L., Dorn M.E., Preffer F.I., Hasserjian R.P. Beyond the lymphocyte predominant cell: CD4+CD8+ T-cells in nodular lymphocyte predominant Hodgkin lymphoma. Leuk. Lymphoma 2008, 49:1870-1878.
37. Das G., Augustine M.M., Das J., Bottomly K., Ray P., Ray A. An important regulatory role for CD4+CD8 alpha alpha T cells in the intestinal epithelial layer in the prevention of inflammatory bowel disease. Proc. Natl. Acad. Sci. USA 2003, 100:5324-5329.
38. Nascimbeni M., Shin E.C., Chiriboga L., Kleiner D.E., Rehermann B. Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood 2004, 104:478-486.
39. Kundu J.K., Surh Y.J. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 2008, 269:243-261.
40. Kalra N., Roy P., Prasad S., Shukla Y. Resveratrol induces apoptosis involving mitochondrial pathways in mouse skin tumorigenesis. Life Sci. 2008, 82:348-358.
41. Lee M.H., Choi B.Y., Kundu J.K., Shin Y.K., Na H.K., Surh Y.J. Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res. 2009, 69:7449-7458.
42. Pan M.H., Gao J.H., Lai C.S., Wang Y.J., Chen W.M., Lo C.Y., Wang M., Dushenkov S., Ho C.T. Antitumor activity of 3,5,4'-trimethoxystilbene in COLO 205 cells and xenografts in SCID mice. Mol. Carcinogen. 2008, 47:184-196.
43. Garvin S., Ollinger K., Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 2006, 231:113-122.
44. Su J.L., Lin M.T., Hong C.C., Chang C.C., Shiah S.G., Wu C.W., Chen S.T., Chau Y.P., Kuo M.L. Resveratrol induces FasL-related apoptosis through Cdc42 activation of ASK1/JNK-dependent signaling pathway in human leukemia HL-60 cells. Carcinogenesis 2005, 26:1-10.
45. Atten M.J., Godoy-Romero E., Attar B.M., Milson T., Zopel M., Holian O. Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells. Invest. New Drug. 2005, 23:111-119.
46. Tsan M.F., White J.E., Maheshwari J.G., Bremner T.A., Sacco J. Resveratrol induces Fas signalling-independent apoptosis in THP-1 human monocytic leukaemia cells. Brit. J. Haematol. 2000, 109:405-412.
47. Dorrie J., Gerauer H., Wachter Y., Zunino S.J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 2001, 61:4731-4739.
48. Kuo P.L., Chiang L.C., Lin C.C. Resveratrol- induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci. 2002, 72:23-34.
49. Wang Q., Li H., Wang X.W., Wu D.C., Chen X.Y., Liu J. Resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells. Neurosci. Lett. 2003, 351:83-86.
50. Kim M.Y., Trudel L.J., Wogan G.N. Apoptosis induced by capsaicin and resveratrol in colon carcinoma cells requires nitric oxide production and caspase activation. Anticancer Res. 2009, 29:3733-3740.
51. Barnhart B.C., Alappat E.C., Peter M.E. The CD95 type I/type II model. Semin. Immunol. 2003, 15:185-193.
52. Guicciardi M.E., Gores G.J. Life and death by death receptors. FASEB J. 2009, 23:1625-1637.
53. Delmas D., Rebe C., Lacour S., Filomenko R., Athias A., Gambert P., Cherkaoui-Malki M., Jannin B., Dubrez-Daloz L., Latruffe N., Solary E. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J. Biol. Chem. 2003, 278:41482-41490.
54. Nishikori M., Maesako Y., Ueda C., Kurata M., Uchiyama T., Ohno H. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood 2003, 101:2789-2796.
55. Kelleher F.C., McDermott R. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur. J. Cancer 2010.
56. Palmer R.H., Vernersson E., Grabbe C., Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem. J. 2009, 420:345-361.
57. McDermott U., Iafrate A.J., Gray N.S., Shioda T., Classon M., Maheswaran S., Zhou W., Choi H.G., Smith S.L., Dowell L., Ulkus L.E., Kuhlmann G., Greninger P., Christensen J.G., Haber D.A., Settleman J. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008, 68:3389-3395.
58. Christensen J.G., Zou H.Y., Arango M.E., Li Q., Lee J.H., McDonnell S.R., Yamazaki S., Alton G.R., Mroczkowski B., Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 2007, 6:3314-3322.
59. Galkin A.V., Melnick J.S., Kim S., Hood T.L., Li N., Li L., Xia G., Steensma R., Chopiuk G., Jiang J., Wan Y., Ding P., Liu Y., Sun F., Schultz P.G., Gray N.S., Warmuth M. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl. Acad. Sci. USA 2007, 104:270-275.
60. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., Ou S.H., Dezube B.J., Janne P.A., Costa D.B., Varella-Garcia M., Kim W.H., Lynch T.J., Fidias P., Stubbs H., Engelman J.A., Sequist L.V., Tan W., Gandhi L., Mino-Kenudson M., Wei G.C., Shreeve S.M., Ratain M.J., Settleman J., Christensen J.G., Haber D.A., Wilner K., Salgia R., Shapiro G.I., Clark J.W., Iafrate A.J. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New Engl. J. Med. 2010, 363:1693-1703.